SWITCH FROM A CNI- TO A BELATACEPT-BASED IMMUNOSUPPRESSIVE REGIMEN IN KIDNEY TRANSPLANT RECIPIENTS IS SAFE AND RESULTS IN BETTER RENAL FUNCTION: 12 MONTH RESULTS FROM A PHASE II STUDY: 1446